Rare disease specialist Sarepta Therapeutics has joined with Selecta Biosciences in a research pact to develop ways to allow its gene therapies to be re-dosed.
Swedish biotech Calliditas has raised $90 million in an upsized US IPO and private placement, valuing the rare kidney and liver disease specialist at $467 million as the craze for biotech I
Alnylam has revealed the data that forms the basis of its filings for its latest potential rare disease drug lumasiran, but shares dipped after an analyst suggested it could be outperformed
Neuromyelitis optica (NMO) can be a devastating rare disease, but a lack of awareness among doctors means patients are often misdiagnosed for years, while research into cures is sparse.
